23205-90-5 Usage
Uses
Used in Oncology:
2,5-bis[(2-chloroethyl)amino]cyclohexa-2,5-dione is used as a chemotherapeutic agent for the treatment of various types of cancer. It is particularly effective against Hodgkin's disease, non-Hodgkin lymphoma, and certain types of leukemia. The alkylating action of mechlorethamine causes DNA damage in cancer cells, disrupting their ability to divide and proliferate, thereby inhibiting tumor growth.
Used in Clinical Settings:
Due to its high toxicity, 2,5-bis[(2-chloroethyl)amino]cyclohexa-2,5-diene-1,4-dione is mainly administered intravenously in a clinical setting under the supervision of a healthcare professional. This ensures that the dosage is carefully controlled and monitored to minimize the risk of severe side effects, such as bone marrow suppression, nausea, and vomiting.
Check Digit Verification of cas no
The CAS Registry Mumber 23205-90-5 includes 8 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 5 digits, 2,3,2,0 and 5 respectively; the second part has 2 digits, 9 and 0 respectively.
Calculate Digit Verification of CAS Registry Number 23205-90:
(7*2)+(6*3)+(5*2)+(4*0)+(3*5)+(2*9)+(1*0)=75
75 % 10 = 5
So 23205-90-5 is a valid CAS Registry Number.
23205-90-5Relevant academic research and scientific papers
Development of quinone analogues as dynamin GTPase inhibitors
Macgregor, Kylie A.,Abdel-Hamid, Mohammed K.,Odell, Luke R.,Chau, Ngoc,Whiting, Ainslie,Robinson, Phillip J.,McCluskey, Adam
, p. 191 - 206 (2014/08/18)
Virtual screening of the ChemDiversity and ChemBridge compound databases against dynamin I (dynI) GTPase activity identified 2,5-bis-(benzylamino)-1,4- benzoquinone 1 as a 273 ± 106 μM inhibitor. In silico lead optimization and focused library-led synthesis resulted in the development of four discrete benzoquinone/naphthoquinone based compound libraries comprising 54 compounds in total. Sixteen analogues were more potent than lead 1, with 2,5-bis-(4-hydroxyanilino)-1,4-benzoquinone (45) and 2,5-bis(4-carboxyanilino)- 1,4-benzoquinone (49) the most active with IC50 values of 11.1 ± 3.6 and 10.6 ± 1.6 μM respectively. Molecular modelling suggested a number of hydrogen bonding and hydrophobic interactions were involved in stabilization of 49 within the dynI GTP binding site. Six of the most active inhibitors were evaluated for potential inhibition of clathrin-mediated endocytosis (CME). Quinone 45 was the most effective CME inhibitor with an IC50(CME) of 36 ± 16 μM.
